1. [Treatment of HIV infection from the neurologic viewpoint. Therapy must reach the brain].
- Author
-
von Giesen HJ, Köller H, and Arendt G
- Subjects
- AIDS Dementia Complex blood, Anti-HIV Agents adverse effects, Anti-HIV Agents pharmacokinetics, Brain metabolism, Humans, Treatment Outcome, AIDS Dementia Complex drug therapy, Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, Brain drug effects, HIV-1 drug effects
- Abstract
An effective highly active antiretroviral therapy (HAART) can prevent the manifestation of HIV-1-associated encephalopathy. Also, HIV-1-associated minor cognitive/motor deficits--an early form of HIV-1-associated dementia--are improved. Clinically manifest HIV-1-associated encephalopathy is an indication for HAART treatment, irrespective of immune status. To date, minor cognitive and/or motor deficits in the presence of good immune status have not been identified as an indication for HAART treatment. Any CNS-effective treatment should be based on either zidovudine or stavudine, since these substances readily enter the CSF; however, NNRTI can also be applied. Side effects of HAART on the central and peripheral nervous system, as well as interactions with known neurological medicaments must be taken into account.
- Published
- 2002